Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot Phase
The Raison Lab at UW-Madison is currently recruiting for a study, sponsored by the Tiny Blue Dot Foundation, titled “Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot Phase.”
The goal of this study is to identify a method to deliver psilocybin intravenously during sleep. Psilocybin is a drug with temporary psychedelic effects that is not yet approved by the US Food and Drug Administration (FDA), but the FDA has allowed for the use of psilocybin in research.
The target study population is healthy adults, 18-45 years old, not currently taking an antidepressant, preferably who have prior experience with psychedelics.
If interested in participating, you can find out more about the study on clinicaltrials.gov (ID NCT05592379) and/or complete our REDCap survey to see if you are eligible and be contacted by the study team.